A delicate balance between antibody evasion and ACE2 affinity for Omicron BA.2.75
Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved..
Variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have caused successive global waves of infection. These variants, with multiple mutations in the spike protein, are thought to facilitate escape from natural and vaccine-induced immunity and often increase in affinity for ACE2. The latest variant to cause concern is BA.2.75, identified in India where it is now the dominant strain, with evidence of wider dissemination. BA.2.75 is derived from BA.2 and contains four additional mutations in the receptor-binding domain (RBD). Here, we perform an antigenic and biophysical characterization of BA.2.75, revealing an interesting balance between humoral evasion and ACE2 receptor affinity. ACE2 affinity for BA.2.75 is increased 9-fold compared with BA.2; there is also evidence of escape of BA.2.75 from immune serum, particularly that induced by Delta infection, which may explain the rapid spread in India, where where there is a high background of Delta infection. ACE2 affinity appears to be prioritized over greater escape.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
Cell reports - 42(2023), 1 vom: 31. Jan., Seite 111903 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 06.02.2023 Date Revised 20.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.celrep.2022.111903 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM350977321 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM350977321 | ||
| 003 | DE-627 | ||
| 005 | 20240320232924.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.celrep.2022.111903 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1337.xml |
| 035 | |a (DE-627)NLM350977321 | ||
| 035 | |a (NLM)36586406 | ||
| 035 | |a (PII)S2211-1247(22)01802-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Huo, Jiandong |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A delicate balance between antibody evasion and ACE2 affinity for Omicron BA.2.75 |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.02.2023 | ||
| 500 | |a Date Revised 20.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a Variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have caused successive global waves of infection. These variants, with multiple mutations in the spike protein, are thought to facilitate escape from natural and vaccine-induced immunity and often increase in affinity for ACE2. The latest variant to cause concern is BA.2.75, identified in India where it is now the dominant strain, with evidence of wider dissemination. BA.2.75 is derived from BA.2 and contains four additional mutations in the receptor-binding domain (RBD). Here, we perform an antigenic and biophysical characterization of BA.2.75, revealing an interesting balance between humoral evasion and ACE2 receptor affinity. ACE2 affinity for BA.2.75 is increased 9-fold compared with BA.2; there is also evidence of escape of BA.2.75 from immune serum, particularly that induced by Delta infection, which may explain the rapid spread in India, where where there is a high background of Delta infection. ACE2 affinity appears to be prioritized over greater escape | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a ACE2 receptor | |
| 650 | 4 | |a BA.2.75 | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a CP: Immunology | |
| 650 | 4 | |a CP: Microbiology | |
| 650 | 4 | |a RBD | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a antigenic variation | |
| 650 | 4 | |a immune escape | |
| 650 | 4 | |a spike | |
| 650 | 4 | |a variant | |
| 650 | 4 | |a variant of concern | |
| 650 | 7 | |a Angiotensin-Converting Enzyme 2 |2 NLM | |
| 650 | 7 | |a EC 3.4.17.23 |2 NLM | |
| 650 | 7 | |a Antibodies |2 NLM | |
| 700 | 1 | |a Dijokaite-Guraliuc, Aiste |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Chang |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Daming |e verfasserin |4 aut | |
| 700 | 1 | |a Ginn, Helen M |e verfasserin |4 aut | |
| 700 | 1 | |a Das, Raksha |e verfasserin |4 aut | |
| 700 | 1 | |a Supasa, Piyada |e verfasserin |4 aut | |
| 700 | 1 | |a Selvaraj, Muneeswaran |e verfasserin |4 aut | |
| 700 | 1 | |a Nutalai, Rungtiwa |e verfasserin |4 aut | |
| 700 | 1 | |a Tuekprakhon, Aekkachai |e verfasserin |4 aut | |
| 700 | 1 | |a Duyvesteyn, Helen M E |e verfasserin |4 aut | |
| 700 | 1 | |a Mentzer, Alexander J |e verfasserin |4 aut | |
| 700 | 1 | |a Skelly, Donal |e verfasserin |4 aut | |
| 700 | 1 | |a Ritter, Thomas G |e verfasserin |4 aut | |
| 700 | 1 | |a Amini, Ali |e verfasserin |4 aut | |
| 700 | 1 | |a Bibi, Sagida |e verfasserin |4 aut | |
| 700 | 1 | |a Adele, Sandra |e verfasserin |4 aut | |
| 700 | 1 | |a Johnson, Sile Ann |e verfasserin |4 aut | |
| 700 | 1 | |a Paterson, Neil G |e verfasserin |4 aut | |
| 700 | 1 | |a Williams, Mark A |e verfasserin |4 aut | |
| 700 | 1 | |a Hall, David R |e verfasserin |4 aut | |
| 700 | 1 | |a Plowright, Megan |e verfasserin |4 aut | |
| 700 | 1 | |a Newman, Thomas A H |e verfasserin |4 aut | |
| 700 | 1 | |a Hornsby, Hailey |e verfasserin |4 aut | |
| 700 | 1 | |a de Silva, Thushan I |e verfasserin |4 aut | |
| 700 | 1 | |a Temperton, Nigel |e verfasserin |4 aut | |
| 700 | 1 | |a Klenerman, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Barnes, Eleanor |e verfasserin |4 aut | |
| 700 | 1 | |a Dunachie, Susanna J |e verfasserin |4 aut | |
| 700 | 1 | |a Pollard, Andrew J |e verfasserin |4 aut | |
| 700 | 1 | |a Lambe, Teresa |e verfasserin |4 aut | |
| 700 | 1 | |a Goulder, Philip |e verfasserin |4 aut | |
| 700 | 0 | |a OPTIC consortium |e verfasserin |4 aut | |
| 700 | 0 | |a ISARIC4C consortium |e verfasserin |4 aut | |
| 700 | 1 | |a Fry, Elizabeth E |e verfasserin |4 aut | |
| 700 | 1 | |a Mongkolsapaya, Juthathip |e verfasserin |4 aut | |
| 700 | 1 | |a Ren, Jingshan |e verfasserin |4 aut | |
| 700 | 1 | |a Stuart, David I |e verfasserin |4 aut | |
| 700 | 1 | |a Screaton, Gavin R |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cell reports |d 2012 |g 42(2023), 1 vom: 31. Jan., Seite 111903 |w (DE-627)NLM217067492 |x 2211-1247 |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2023 |g number:1 |g day:31 |g month:01 |g pages:111903 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.celrep.2022.111903 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 42 |j 2023 |e 1 |b 31 |c 01 |h 111903 | ||